Filtered By:
Countries: Australia Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 48410 results found since Jan 2013.

Tropical Travel Trouble 009 Humongous HIV Extravaganza
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog aka Tropical Travel Trouble 009 The diagnosis of HIV is no longer fatal and the term AIDS is becoming less frequent. In many countries, people with HIV are living longer than those with diabetes. This post will hopefully teach the basics of a complex disease and demystify some of the potential diseases you need to consider in those who are severely immunosuppressed. While trying to be comprehensive this post can not be exhaustive (as you can imagine any patient with a low ...
Source: Life in the Fast Lane - July 7, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine AIDS art cryptococcoma cryptococcus HIV HIV1 HIV2 PEP PrEP TB toxoplasma tuberculoma Source Type: blogs

The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS
Publication date: Available online 11 March 2018 Source:The Lancet HIV Author(s): Sherrie L Kelly, Rowan Martin-Hughes, Robyn M Stuart, Xiao F Yap, David J Kedziora, Kelsey L Grantham, S Azfar Hussain, Iyanoosh Reporter, Andrew J Shattock, Laura Grobicki, Hassan Haghparast-Bidgoli, Jolene Skordis-Worrall, Zofia Baranczuk, Olivia Keiser, Janne Estill, Janka Petravic, Richard T Gray, Clemens J Benedikt, Nicole Fraser, Marelize Gorgens, David Wilson, Cliff C Kerr, David P Wilson Background To move towards ending AIDS by 2030, HIV resources should be allocated cost-effectively. We used the Optima HIV model to estimate how glo...
Source: The Lancet HIV - March 12, 2018 Category: Infectious Diseases Source Type: research

Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study
Publication date: Available online 17 July 2018Source: The Lancet HIVAuthor(s): Benjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, Beatriz Grinsztejn, Garrett P Prestage, Iryna B Zablotska-Manos, Fengyi Jin, Christopher K Fairley, Richard Moore, Norman Roth, Mark Bloch, Catherine Pell, Anna M McNulty, David Baker, Jennifer Hoy, Ban Kiem Tee, David J Templeton, David A Cooper, Sean Emery, Anthony KelleherSummaryBackgroundEvidence on viral load and HIV transmission risk in HIV-serodiscordant male homosexual couples is limited to one published study. We calculated transmission rates in couples reporting condomless anal in...
Source: The Lancet HIV - July 18, 2018 Category: Infectious Diseases Source Type: research

HIV incidence in Indigenous and non-Indigenous populations in Australia: a population-level observational study
Publication date: Available online 7 August 2018Source: The Lancet HIVAuthor(s): James Ward, Hamish McManus, Skye McGregor, Karen Hawke, Carolien Giele, Jiunn-Yih Su, Ann McDonald, Rebecca Guy, Basil Donovan, John M KaldorSummaryBackgroundAustralia has set a national target of ending HIV by 2020, achieving this will require the inclusion of priority populations (eg, Indigenous Australians) in strategies to reach elimination. To assist in evaluating the target of elimination, we analysed HIV notification data for Indigenous and non-Indigenous Australians.MethodsUsing the National HIV Registry at The Kirby Institute at UNSW,...
Source: The Lancet HIV - August 8, 2018 Category: Infectious Diseases Source Type: research

What Researchers Have Learned About Whether it ’s Possible to ‘Cure’ HIV
It’s the news that the HIV community has been waiting four long decades for: the hint that maybe, just maybe, HIV can be cured. Dr. Xu Yu, a principal investigator at the Ragon Institute of Massachusetts General Hospital, MIT and Harvard, as well as an associate professor of medicine at Harvard Medical School, had to check and recheck her results to be sure. In one of her patients, test after test to detect evidence of HIV in the woman’s blood came up empty. In addition to her lab’s results, “We had complementary assays in labs in Australia, D.C. and Argentina, where the patient is from, all trying ...
Source: TIME: Health - November 30, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate HIV/AIDS Source Type: news

The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial
Publication date: Available online 8 April 2018 Source:The Lancet HIV Author(s): Thomas A Rasmussen, James H McMahon, J Judy Chang, Jennifer Audsley, Ajantha Rhodes, Surekha Tennakoon, Ashanti Dantanarayana, Tim Spelman, Tina Schmidt, Stephen J Kent, Vincent Morcilla, Sarah Palmer, Julian H Elliott, Sharon R Lewin Background Whether ongoing virus replication occurs in HIV-infected individuals on antiretroviral therapy (ART) is unclear; therefore, whether residual virus replication is a barrier to achieving a cure for HIV is also unknown. We aimed to establish whether ART intensification with dolutegravir would reveal or a...
Source: The Lancet HIV - April 9, 2018 Category: Infectious Diseases Source Type: research

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study
We report protocol-specified co-primary outcomes at 12 months after recruitment of the first 3700 participants: within-cohort HIV incidence; and change in population HIV diagnoses in New South Wales between the 12-month periods before and after PrEP roll-out. The study is registered with ClinicalTrials.gov, number NCT02870790.FindingsWe recruited 3700 participants in the 8 months between March 1, 2016, and Oct 31, 2016. 3676 (99%) were men, 3534 (96%) identified as gay, and 149 (4%) as bisexual. Median age was 36 years (IQR 30–45 years). Overall, 3069 (83%) participants attended a visit at 12 months or later. Over 4100 p...
Source: The Lancet HIV - October 18, 2018 Category: Infectious Diseases Source Type: research

Monthly Shots of HIV Drugs Are as Effective as Daily Pills, 2 Big Studies Show
SEATTLE (AP) — Monthly shots of HIV drugs worked as well as daily pills to control the virus that causes AIDS in two large international tests, researchers reported Thursday. If approved by regulators in the United States and Europe, the shots would be a new option for people with HIV and could help some stay on treatment. Instead of having to remember to take pills, patients instead could get injections from a doctor or nurse each month. “Some people will be thrilled” at the convenience, said Mitchell Warren, executive director of AVAC, an AIDS advocacy group. Condoms remain the most widely available and...
Source: TIME: Health - March 7, 2019 Category: Consumer Health News Authors: CARLA K. JOHNSON / AP Tags: Uncategorized AIDS/HIV anti hiv drugs onetime Source Type: news

Scaling up preexposure prophylaxis to maximize HIV prevention impact
Purpose of review Ten years since the first regulatory approval of oral HIV preexposure prophylaxis (PrEP), this review summarizes PrEP uptake, the role of ambitious PrEP targets, emerging evidence of impact on the HIV epidemic and innovative approaches to increasing PrEP uptake. Recent findings PrEP uptake among people at risk of HIV has been slow, but has accelerated in recent years, particularly in gay and bisexual men in a limited number of high-income settings and recently in heterosexuals at risk of HIV in sub-Saharan Africa. However, UNAIDS 2020 PrEP targets and HIV prevention targets were missed by large...
Source: Current Opinion in HIV and AIDS - July 1, 2022 Category: Infectious Diseases Tags: PREP (PRE-EXPOSURE PROPHYLAXIS): Edited by Jean-Michel Molina Source Type: research

Health and medical professionals antenatal HIV testing practices and perceived barriers to routine testing in Tasmania, Australia: a qualitative study
Conclusion Antenatal HIV testing is undertaken within a discordant discourse generating clinical hesitancy where HIV is perceived as a theoretical risk and surrounded by stigma. Using neutral language and replacing the words ‘routine’ and ‘recommended’ with ‘universal’ testing in public health policy and clinical guidelines could increase health providers’ confidence and reduce ambiguity and the legacy of HIV stigma.
Source: BMJ Open - March 6, 2023 Category: General Medicine Authors: Ayton, J. E., Bennett-Daly, G., Nguyen, A., Owen, L. Tags: Open access HIV/AIDS Source Type: research

Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)
Background: There are few data regarding clinical care and outcomes of Indigenous Australians living with HIV and it is unknown if these differ from non-Indigenous HIV-positive Australians. Methods: AHOD commenced enrolment in 1999 and is a prospective cohort of HIV-positive participants attending HIV outpatient services throughout Australia, of which 20 (74 %) sites report Indigenous status. Data were collected up until March 2013 and compared between Indigenous and non-Indigenous participants. Person-year methods were used to compare death rates, rates of loss to follow-up and rates of laboratory testing during follow-u...
Source: BMC Infectious Diseases - August 12, 2015 Category: Infectious Diseases Authors: David TempletonStephen WrightHamish McManusChris LawrenceDarren RussellMatthew LawKathy Petoumenoson behalf of the Australian HIV Observational Database Source Type: research

Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial
Publication date: Available online 23 September 2018Source: The Lancet HIVAuthor(s): Stephen J Kent, Sally Hough, Anthony D Kelleher, Matthew G Law, Jolie Hutchinson, Marta Catalfarmo, Cliff Lane, Jason V Baker, Sean EmerySummaryBackgroundIncreased D-dimer concentrations are associated with poor cardiovascular and other clinical outcomes in people with treated HIV infection. Proteinase activated receptor-1 (PAR-1) is activated by thrombin and overexpressed by immune cells from HIV-infected people. We aimed to study the efficacy of vorapaxar, a licensed inhibitor of PAR-1, in reducing HIV-associated hypercoagulation and inf...
Source: The Lancet HIV - October 5, 2018 Category: Infectious Diseases Source Type: research

Groundbreaking Australian HIV trial should be replicated, researchers say
Trial resulted in 25% fall in new infections in year after rapid rollout of PrEP medicationHigh-income countries with people at high risk of HIV should replicate a groundbreaking trial in Australia, which has seen new infections fall by 25% in one year following the rapid rollout of free HIV medication, researchers say.When taken daily the pre-exposure prophylaxis drug known as PrEP is almost 100% effective in preventing HIV-negative people from acquiring the virus. In 2016, NSW became the first Australian state to trial PrEP on a large scale. In the course of just one year 9,714 HIV-negative people at high risk of acquiri...
Source: Guardian Unlimited Science - October 17, 2018 Category: Science Authors: Melissa Davey Tags: Aids and HIV Health Medical research Australia news Source Type: news

Cardiovascular disease and diabetes in HIV ‐positive and HIV‐negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study
ConclusionsHIV ‐positive GBM more commonly reported heart disease and thrombosis compared with their HIV‐negative peers. These results further highlight the need to understand the impact of HIV on age‐related comorbidities in GBM, to guide optimal screening and treatment strategies to reduce the risk of thes e comorbidities among the HIV‐positive population.
Source: HIV Medicine - November 26, 2018 Category: Infectious Diseases Authors: R Puhr, K Petoumenos, R Huang, DJ Templeton, I Woolley, M Bloch, D Russell, MG Law, DA Cooper Tags: Original Research Source Type: research

Brain amyloid in virally suppressed HIV-associated neurocognitive disorder
Conclusions Relative to cognitively normal older controls, brain amyloid burden does not differ in virally suppressed HAND at the group level. However, individual analyses show that abnormally high and low amyloid burden occur.
Source: Neurology Neuroimmunology and Neuroinflammation - May 10, 2020 Category: Neurology Authors: Howdle, G. C., Quide, Y., Kassem, M. S., Johnson, K., Rae, C. D., Brew, B. J., Cysique, L. A. Tags: PET, Neuropsychological assessment, Alzheimer's disease, HIV dementia, MCI (mild cognitive impairment) Article Source Type: research